Optically Reversible News Today

/PRNewswire/ -- ILIAS Biologics Inc., a biotech company dedicated to developing a new treatment modality, engineered exosome therapeutics, announced today that...

Share this article Share this article DAEJEON, South Korea, Feb. 1, 2021 /PRNewswire/ -- ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIASs anti-inflammatory exosomes devel...

The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the 'fetus as the patient'.

 E-Mail GALVESTON, Texas - The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the fetus as the patient. The study has been published in Science Advances. It has long been suspected that pre-term labor is triggered by inflammation caused by a sick fetus. A new study by scientists at UTMB has proved the hypothesis...